Cross-linking is the only approved treatment for halting the progression of keratoconus. Dr. Price, one of the most experienced surgeons at performing cross-linking in the United States, contributed to FDA approval of cross-linking and served as an investigator in the original USA clinical trials, starting back in 2008. As a result of these studies, the FDA determined that cross linking is a safe and effective treatment. The Price Vision Group team has also participated in some more recent clinical trials for advancements in cross-linking that are not yet approved.
The cross-linking procedure involves the combined use of riboflavin (vitamin B2) eye drops and UVA light to strengthen the front layers of the cornea. The company that received the FDA approval expects to have the riboflavin and UVA light commercially available by the end of 2016. Until then, Price Vision Group is providing patients access to cross-linking through an ongoing investigational study.
For more information and to find out if you may be a candidate, please contact our office at (800) 317-3937 to schedule an appointment for an evaluation. You can also CLICK HERE for a brochure from the Cornea Research Foundation of America with more information about keratoconus and cross-linking. Please note that this brochure discusses the research study on cross-linking conducted jointly with the Price Vision Group, but the study has ended now that the procedure has been approved by the US Food and Drug Administration in April, 2016. Despite the FDA approval, corneal cross-linking is currently still considered investigational and not covered by most medical insurance companies.